Celgene Corporation (CELG) Shares Sold by 1832 Asset Management L.P., Report finds

Celgene Corporation (CELG) Shares Sold by 1832 Asset Management L.P., Report finds

1832 Asset Management L.P. reduced its stake in Celgene Corporation (NASDAQ:CELG) by 22.4% during the third quarter, Holdings Channel reports. The fund owned 243,519 shares of the biopharmaceutical company’s stock after selling 70,365 shares during the period. 1832 Asset Management L.P.’s holdings in Celgene Corporation were worth $25,231,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its position in shares of Celgene Corporation by 1.4% in the second quarter. LS Investment Advisors LLC now owns 10,690 shares of the biopharmaceutical company’s stock valued at $1,054,000 after buying an additional 152 shares during the last quarter. Riggs Asset Managment Co. Inc. boosted its position in shares of Celgene Corporation by 299.5% in the second quarter. Riggs Asset Managment Co. Inc. now owns 9,589 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 7,189 shares during the last quarter. Atlas Brown Inc. boosted its position in Celgene Corporation by 2.9% in the second quarter. Atlas Brown Inc. now owns 4,285 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 120 shares during the last quarter. Tealwood Asset Management Inc. boosted its position in Celgene Corporation by 2.8% in the second quarter. Tealwood Asset Management Inc. now owns 16,028 shares of the biopharmaceutical company’s stock worth $1,581,000 after buying an additional 444 shares during the last quarter. Finally, Rock Point Advisors LLC bought a new position in Celgene Corporation during the second quarter worth $201,000. Institutional investors own 77.16% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 0.78% on Wednesday, hitting $115.35. The stock had a trading volume of 3,285,859 shares. The company has a market cap of $89.42 billion, a price-to-earnings ratio of 46.33 and a beta of 1.74. The stock has a 50 day moving average price of $116.19 and a 200-day moving average price of $111.62. Celgene Corporation has a 12-month low of $94.39 and a 12-month high of $127.00.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.59 by $0.02. The firm earned $2.98 billion during the quarter, compared to analyst estimates of $3.03 billion. Celgene Corporation had a return on equity of 77.95% and a net margin of 17.80%. Celgene Corporation’s revenue was up 16.3% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. On average, equities analysts expect that Celgene Corporation will post $7.22 earnings per share for the current year.

A number of research analysts have recently weighed in on CELG shares. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, October 15th. Jefferies Group LLC reaffirmed a “buy” rating and set a $134.00 price objective on shares of Celgene Corporation in a research report on Monday, October 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $141.00 price objective on shares of Celgene Corporation in a research report on Monday, October 17th. Cowen and Company reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Tuesday, October 18th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $140.00 price objective on shares of Celgene Corporation in a research report on Tuesday, October 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, twenty-four have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $138.78.

Celgene Corporation Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Related posts

Leave a Comment

Celgene Corporation (CELG) Shares Sold by 1832 Asset Management L.P.

Celgene Corporation (CELG) Shares Sold by 1832 Asset Management L.P.

1832 Asset Management L.P. reduced its stake in Celgene Corporation (NASDAQ:CELG) by 22.4% during the third quarter, Holdings Channel reports. The fund owned 243,519 shares of the biopharmaceutical company’s stock after selling 70,365 shares during the period. 1832 Asset Management L.P.’s holdings in Celgene Corporation were worth $25,231,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its position in shares of Celgene Corporation by 1.4% in the second quarter. LS Investment Advisors LLC now owns 10,690 shares of the biopharmaceutical company’s stock valued at $1,054,000 after buying an additional 152 shares during the last quarter. Riggs Asset Managment Co. Inc. boosted its position in shares of Celgene Corporation by 299.5% in the second quarter. Riggs Asset Managment Co. Inc. now owns 9,589 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 7,189 shares during the last quarter. Atlas Brown Inc. boosted its position in Celgene Corporation by 2.9% in the second quarter. Atlas Brown Inc. now owns 4,285 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 120 shares during the last quarter. Tealwood Asset Management Inc. boosted its position in Celgene Corporation by 2.8% in the second quarter. Tealwood Asset Management Inc. now owns 16,028 shares of the biopharmaceutical company’s stock worth $1,581,000 after buying an additional 444 shares during the last quarter. Finally, Rock Point Advisors LLC bought a new position in Celgene Corporation during the second quarter worth $201,000. Institutional investors own 77.16% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 0.78% on Wednesday, hitting $115.35. The stock had a trading volume of 3,285,859 shares. The company has a market cap of $89.42 billion, a price-to-earnings ratio of 46.33 and a beta of 1.74. The stock has a 50 day moving average price of $116.19 and a 200-day moving average price of $111.62. Celgene Corporation has a 12-month low of $94.39 and a 12-month high of $127.00.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.59 by $0.02. The firm earned $2.98 billion during the quarter, compared to analyst estimates of $3.03 billion. Celgene Corporation had a return on equity of 77.95% and a net margin of 17.80%. Celgene Corporation’s revenue was up 16.3% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. On average, equities analysts expect that Celgene Corporation will post $7.22 earnings per share for the current year.

A number of research analysts have recently weighed in on CELG shares. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, October 15th. Jefferies Group LLC reaffirmed a “buy” rating and set a $134.00 price objective on shares of Celgene Corporation in a research report on Monday, October 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $141.00 price objective on shares of Celgene Corporation in a research report on Monday, October 17th. Cowen and Company reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Tuesday, October 18th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $140.00 price objective on shares of Celgene Corporation in a research report on Tuesday, October 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, twenty-four have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $138.78.

Celgene Corporation Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Related posts

Leave a Comment